201 related articles for article (PubMed ID: 21767952)
21. Structure-activity relationship study of tricyclic necroptosis inhibitors.
Jagtap PG; Degterev A; Choi S; Keys H; Yuan J; Cuny GD
J Med Chem; 2007 Apr; 50(8):1886-95. PubMed ID: 17361994
[TBL] [Abstract][Full Text] [Related]
22. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
23. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
[TBL] [Abstract][Full Text] [Related]
24. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.
Aronov AM; Baker C; Bemis GW; Cao J; Chen G; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Martinez-Botella G; Namchuk MN; Straub J; Tang Q; Xie X
J Med Chem; 2007 Mar; 50(6):1280-7. PubMed ID: 17300186
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
Cheruvallath Z; Tang M; McBride C; Komandla M; Miura J; Ton-Nu T; Erikson P; Feng J; Farrell P; Lawson JD; Vanderpool D; Wu Y; Dougan DR; Plonowski A; Holub C; Larson C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2774-2778. PubMed ID: 27155900
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).
Huard K; Ahn K; Amor P; Beebe DA; Borzilleri KA; Chrunyk BA; Coffey SB; Cong Y; Conn EL; Culp JS; Dowling MS; Gorgoglione MF; Gutierrez JA; Knafels JD; Lachapelle EA; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Raymer B; Ross TT; Shavnya A; Smith AC; Subashi TA; Tesz GJ; Thuma BA; Tu M; Weaver JD; Weng Y; Withka JM; Xing G; Magee TV
J Med Chem; 2017 Sep; 60(18):7835-7849. PubMed ID: 28853885
[TBL] [Abstract][Full Text] [Related]
27. Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.
Fukuda T; Goto R; Kiho T; Ueda K; Muramatsu S; Hashimoto M; Aki A; Watanabe K; Tanaka N
Bioorg Med Chem Lett; 2017 Dec; 27(23):5252-5257. PubMed ID: 29079471
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
29. Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity.
Ali A; Thompson CF; Balkovec JM; Graham DW; Hammond ML; Quraishi N; Tata JR; Einstein M; Ge L; Harris G; Kelly TM; Mazur P; Pandit S; Santoro J; Sitlani A; Wang C; Williamson J; Miller DK; Thompson CM; Zaller DM; Forrest MJ; Carballo-Jane E; Luell S
J Med Chem; 2004 May; 47(10):2441-52. PubMed ID: 15115388
[TBL] [Abstract][Full Text] [Related]
30. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.
Ward SE; Harries M; Aldegheri L; Austin NE; Ballantine S; Ballini E; Bradley DM; Bax BD; Clarke BP; Harris AJ; Harrison SA; Melarange RA; Mookherjee C; Mosley J; Dal Negro G; Oliosi B; Smith KJ; Thewlis KM; Woollard PM; Yusaf SP
J Med Chem; 2011 Jan; 54(1):78-94. PubMed ID: 21128618
[TBL] [Abstract][Full Text] [Related]
31. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
32. A novel series of positive modulators of the AMPA receptor: structure-based lead optimization.
Jamieson C; Campbell RA; Cumming IA; Gillen KJ; Gillespie J; Kazemier B; Kiczun M; Lamont Y; Lyons AJ; Maclean JK; Martin F; Moir EM; Morrow JA; Pantling J; Rankovic Z; Smith L
Bioorg Med Chem Lett; 2010 Oct; 20(20):6072-5. PubMed ID: 20817521
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
Gökhan-Kelekçi N; Simşek OO; Ercan A; Yelekçi K; Sahin ZS; Işik S; Uçar G; Bilgin AA
Bioorg Med Chem; 2009 Sep; 17(18):6761-72. PubMed ID: 19682910
[TBL] [Abstract][Full Text] [Related]
35. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a new HIV-1 inhibitor scaffold and synthesis of potential prodrugs of indazoles.
Kim SH; Markovitz B; Trovato R; Murphy BR; Austin H; Willardsen AJ; Baichwal V; Morham S; Bajji A
Bioorg Med Chem Lett; 2013 May; 23(10):2888-92. PubMed ID: 23566519
[TBL] [Abstract][Full Text] [Related]
37. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
[TBL] [Abstract][Full Text] [Related]
38. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.
Bhattacharya SK; Aspnes GE; Bagley SW; Boehm M; Brosius AD; Buckbinder L; Chang JS; Dibrino J; Eng H; Frederick KS; Griffith DA; Griffor MC; Guimarães CR; Guzman-Perez A; Han S; Kalgutkar AS; Klug-McLeod J; Garcia-Irizarry C; Li J; Lippa B; Price DA; Southers JA; Walker DP; Wei L; Xiao J; Zawistoski MP; Zhao X
Bioorg Med Chem Lett; 2012 Dec; 22(24):7523-9. PubMed ID: 23153798
[TBL] [Abstract][Full Text] [Related]
40. PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
Dounay AB; Anderson M; Bechle BM; Evrard E; Gan X; Kim JY; McAllister LA; Pandit J; Rong S; Salafia MA; Tuttle JB; Zawadzke LE; Verhoest PR
Bioorg Med Chem Lett; 2013 Apr; 23(7):1961-6. PubMed ID: 23466229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
